Guggenheim Increases Aclaris Therapeutics Inc (ACRS) Price Target to $40.00

Aclaris Therapeutics Inc (NASDAQ:ACRS) had its target price hoisted by Guggenheim from $35.00 to $40.00 in a research report report published on Wednesday. Guggenheim currently has a buy rating on the stock.

ACRS has been the topic of several other research reports. Zacks Investment Research downgraded shares of Aclaris Therapeutics from a buy rating to a hold rating in a report on Thursday, March 2nd. Leerink Swann started coverage on shares of Aclaris Therapeutics in a report on Tuesday, November 29th. They issued an outperform rating on the stock. Finally, Jefferies Group LLC reaffirmed a buy rating and issued a $32.00 price target (up previously from $29.00) on shares of Aclaris Therapeutics in a report on Friday, November 18th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average price target of $36.25.

Shares of Aclaris Therapeutics (NASDAQ:ACRS) opened at 28.88 on Wednesday. The company has a 50-day moving average of $28.79 and a 200 day moving average of $26.33. Aclaris Therapeutics has a 12-month low of $14.12 and a 12-month high of $33.25. The firm’s market cap is $618.96 million.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings results on Wednesday, March 15th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.10. Equities research analysts anticipate that Aclaris Therapeutics will post ($3.11) earnings per share for the current fiscal year.

var userip;Your IP Address: document.write(userip);

In related news, major shareholder Ventures Fund Vii L.P. Vivo sold 425,000 shares of the company’s stock in a transaction that occurred on Thursday, March 2nd. The shares were sold at an average price of $30.82, for a total transaction of $13,098,500.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Anand Mehra sold 750,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 10th. The shares were sold at an average price of $28.25, for a total transaction of $21,187,500.00. The disclosure for this sale can be found here. Corporate insiders own 46.40% of the company’s stock.

Several institutional investors have recently made changes to their positions in ACRS. Norges Bank purchased a new position in shares of Aclaris Therapeutics during the fourth quarter valued at about $900,000. EcoR1 Capital LLC purchased a new position in shares of Aclaris Therapeutics during the fourth quarter valued at about $11,236,000. Boothbay Fund Management LLC purchased a new position in shares of Aclaris Therapeutics during the fourth quarter valued at about $264,000. Perceptive Advisors LLC purchased a new position in shares of Aclaris Therapeutics during the fourth quarter valued at about $34,219,000. Finally, Deerfield Management Co. increased its position in shares of Aclaris Therapeutics by 223.3% in the fourth quarter. Deerfield Management Co. now owns 375,000 shares of the company’s stock valued at $10,178,000 after buying an additional 259,000 shares during the last quarter. 61.94% of the stock is currently owned by institutional investors and hedge funds.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to address the needs in dermatology. Its lead drug candidate, A-101 Topical Solution, is a hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK).

5 Day Chart for NASDAQ:ACRS

Receive News & Ratings for Aclaris Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Burberry Misses Estimates on Sales
Burberry Misses Estimates on Sales
Snapchat: CEO Did Not Label India as Being Poor
Snapchat: CEO Did Not Label India as Being Poor
Credit Suisse Slashes Bonuses by 40%
Credit Suisse Slashes Bonuses by 40%
Daily Mail to Pay Melania Trump $3 Million
Daily Mail to Pay Melania Trump $3 Million
New York Approves Free College Tuition
New York Approves Free College Tuition
Obamacare Market in Iowa Hit Hard by Aetna
Obamacare Market in Iowa Hit Hard by Aetna


© 2006-2017 Ticker Report. Google+.